[1]周宏灏.遗传药理学.2版.北京：科学出版社，2013.

[2]Manolio TA，Chisholm RL，Ozenberger B，et al.Implementing genomic medicine in the clinic：the future is now.Genet Med，2013，15（4)：258-267.

[3]http：//www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378. htm.

[4]https：//www.pharmgkb.org/view/dosing-guidelines.do.

[5]http：//www.biodiscover.com/news/politics/120902.html.

[6]Hodoglugil U，Carrillo MW，Hebert JM，et al.PharmGKB summary：very important pharmacogene information for the epidermal growth factor receptor.Pharmacogenet Genomics，2013，23（11)：636-642.

[7]Finkelman BS，Gage BF，Johnson JA，etal.Genetic warfarin dosing：tables versus algorithms. JAm Coll Cardiol，2011，57（5)：612-618.

[8]Ann K Daly.Pharmacogenomics of adverse drug reactions.Genome Medicine，2013，5（1)：5.

[9]Julia M.Barbarino，Deanna L.etal.PharmGKB summary：very importantpharmacogene information for human leukocyte antigen B.Pharmacogenetics and Genomics，2015，25：205-221.

[10]Nahoko Kaniwa and Yoshiro Saito.Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.JHum Genet，2013，58：317-326.